Scarica l'app Stockscreener
2.58
8.19%
-0.23
Dopo l'orario di chiusura:
2.56
-0.02
-0.78%
Precedente Chiudi:
$2.81
Aprire:
$2.91
Volume 24 ore:
60,397
Relative Volume:
0.31
Capitalizzazione di mercato:
$8.07M
Reddito:
-
Utile/perdita netta:
$-17.85M
Rapporto P/E:
-0.0696
EPS:
-37.0644
Flusso di cassa netto:
$-13.02M
1 W Prestazione:
-15.96%
1M Prestazione:
-9.15%
6M Prestazione:
-80.33%
1 anno Prestazione:
-95.11%
Intervallo 1D:
$2.5306
$2.91
Intervallo di 1 settimana:
$2.5306
$3.13
Portata 52W:
$2.13
$53.85
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Nome
Silexion Therapeutics Corp
Settore
Industria
Telefono
972-8-6286005
Indirizzo
12 ABBA HILLEL ROAD, RAMAT GAN
Confronta SLXN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
2.58 | 8.79M | 0 | -17.85M | -13.02M | -37.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Silexion Therapeutics Corp Borsa (SLXN) Ultime notizie
Silexion Therapeutics initiated with a Buy at Litchfield Hills - TipRanks
Bearish Setup: Is Silexion Therapeutics Corp Equity Warrant stock recession proof2025 Momentum Check & AI Forecasted Entry/Exit Points - moha.gov.vn
Silexion Shares Decline After Update on German Regulatory Review - MSN
Silexion Therapeutics (SLXNW) Stock Analysis Report | Financials & Insights - Benzinga
How buybacks impact Silexion Therapeutics Corp stock valueProfit Target & Intraday High Probability Setup Alerts - Newser
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment - TipRanks
Silexion Therapeutics drops 18%, prices $5M share offering - MSN
Silexion receives positive feedback from German Health Authority for SIL204 - TipRanks
Silexion Therapeutics (SLXN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion stock falls after receiving German regulatory feedback By Investing.com - Investing.com Canada
Silexion stock falls after receiving German regulatory feedback - Investing.com
Silexion Therapeutics receives positive feedback from German health authority on design of phase 2/3 clinical trial - marketscreener.com
Silexion Therapeutics Gains Positive Feedback for SIL204 Trial - TipRanks
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - GlobeNewswire
How Silexion Therapeutics Corp Equity Warrant stock reacts to Fed rate cuts2025 Buyback Activity & Weekly Stock Breakout Alerts - Newser
Aug Mood: Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Catalysts & Consistent Profit Trade Alerts - moha.gov.vn
SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Its Stock Has Paid Off Big Time For Silexion Therapeutics Corp - setenews.com
Silexion Therapeutics completes toxicology studies for SIL204 - MSN
Silexion stock jumps after toxicology studies show no systemic toxicity - MSN
Silexion Completes Toxicology Studies For SIL204; Phase 2/3 Pancreatic Cancer Trial To Begin In Q2 - Nasdaq
Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - marketscreener.com
Silexion stock jumps after toxicology studies show no systemic toxicity By Investing.com - Investing.com Canada
Silexion to begin phase 2/3 pancreatic cancer clinical trial in Q2 2026 - marketscreener.com
Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026 - TradingView
Silexion Completes Toxicology Studies for SIL204 Therapy - TipRanks
Silexion Therapeutics Completes Toxicology Studies for SIL204 - TradingView
SLXN advances SIL204 toward Phase 2/3 pancreatic cancer study - Stock Titan
Silexion Therapeutics Reports Successful Toxicology Study Results for SIL204, Paving the Way for Upcoming Phase 2/3 Clinical Trial in Pancreatic Cancer - Quiver Quantitative
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer - Sahm
Can Silexion Therapeutics Corp hit a new high this monthJuly 2025 Closing Moves & Free High Return Stock Watch Alerts - newser.com
Silexion Therapeutics Corp (SLXN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Silexion Therapeutics Corp stock is rated strong buyQuarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
Will Silexion Therapeutics Corp Equity Warrant price bounce be sustainableJuly 2025 Intraday Action & Safe Entry Point Alerts - newser.com
Real time alert setup for Silexion Therapeutics Corp Equity Warrant performance - newser.com
Will Silexion Therapeutics Corp outperform the marketTrade Signal Summary & Consistent Return Strategy Ideas - newser.com
How Silexion Therapeutics Corp Equity Warrant stock performs in high volatility marketsDollar Strength & Safe Swing Trade Setup Alerts - newser.com
Applying sector rotation models to Silexion Therapeutics Corp Equity WarrantProfit Target & Risk Controlled Stock Alerts - newser.com
Relative strength of Silexion Therapeutics Corp in sector analysisEntry Point & Verified Momentum Watchlists - newser.com
Can Silexion Therapeutics Corp Equity Warrant recover in the next quarterBuy Signal & Technical Pattern Based Signals - newser.com
Why retail investors pile into Silexion Therapeutics Corp Equity Warrant stockEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Is Silexion Therapeutics Corp a good long term investmentPrice Channel Trading & Unlock Patterns Humans Can’t See - earlytimes.in
Silexion Therapeutics Corp Azioni (SLXN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):